Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy Morgan Stanley

Regeneron Pharmaceuticals Inc.
Start price
€779.00
01.11.24 / 50%
Target price
€1,092.0
01.11.25
Performance (%)
-35.71%
Price
€499.10
12:20
Summary
This prediction is currently active. The BUY prediction by Morgan_Stanley for Regeneron Pharmaceuticals Inc. is performing very badly with a performance of -35.71%. Dividends of €1.72 are taken into consideration when calculating the performance. This prediction currently runs until 01.11.25. The prediction end date can be changed by Morgan_Stanley at any time. Morgan_Stanley has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Performance without dividends (%)
Name 1w 1m
Regeneron Pharmaceuticals Inc. 2.606% 2.606%
iShares Core DAX® 0.648% -0.148%
iShares Nasdaq 100 -0.034% 1.859%
iShares Nikkei 225® 2.445% 8.129%
iShares S&P 500 0.492% 1.525%

Comments by Morgan_Stanley for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Buy
Perf. (%) -35.71%
Target price 1092.003
Change
Ends at 01.11.25

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $1,235.00 to $1,184.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat

Morgan Stanley 
0
Report Share
01.11.24

Stopped prediction by Morgan_Stanley for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€479.90
10.07.25
€642.11
10.07.26
4.19%
12:20

Morgan Stanley 
10.07.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€428.20
02.06.25
€664.02
02.06.26
16.77%
12:20

Morgan Stanley 
02.06.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€995.00
11.07.24
€1,087.6
11.07.25
-51.07%
12.07.25

Morgan Stanley 
11.07.24 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€883.50
18.03.24
€1,025.4
18.03.25
-30.96%
19.03.25

Morgan Stanley 
18.03.24 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€764.50
03.11.23
€854.04
03.11.24
1.87%
04.11.24

Morgan Stanley 
03.11.23 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€785.00
11.10.23
€861.38
11.10.24
17.78%
12.10.24

Morgan Stanley 
11.10.23 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€692.50
04.08.23
€828.28
04.08.24
42.96%
05.08.24

Morgan Stanley 
04.08.23 50%